S'abonner

SARS-CoV-2 infection of thymus induces loss of function that correlates with disease severity - 05/04/23

Doi : 10.1016/j.jaci.2023.01.022 
Marco Rosichini, MSc a, b, , Veronica Bordoni, PhD a, c, , Domenico Alessandro Silvestris, PhD a, Davide Mariotti, MSc c, Giulia Matusali, PhD d, Antonella Cardinale, MSc a, Giovanna Zambruno, MD e, Angelo Giuseppe Condorelli, PhD e, Sara Flamini, PhD a, Shirley Genah, PhD a, Marialuigia Catanoso, MD a, f, Franca Del Nonno, MD g, Matteo Trezzi, MD h, Lorenzo Galletti, MD h, Cristiano De Stefanis, MSc i, Nicolò Cicolani, BSc j, Stefania Petrini, PhD j, Concetta Quintarelli, PhD a, k, Chiara Agrati, PhD a, c, , Franco Locatelli, MD a, l, , Enrico Velardi, PhD a,
a Department of Pediatric Hematology and Oncology, Cell and Gene Therapy, Bambino Gesù Children’s Hospital, IRCCS, Rome, Italy 
e Genodermatosis Unit, Genetics and Rare Diseases Research Division, Bambino Gesù Children’s Hospital, IRCCS, Rome, Italy 
h Cardiac Surgery Unit, Department of Pediatric Cardiology and Cardiac Surgery, Bambino Gesù Children’s Hospital, IRCCS, Rome, Italy 
i Pathology Unit, Core Research Laboratories, Bambino Gesù Children’s Hospital, IRCCS, Rome, Italy 
j Confocal Microscopy Core Facility, Research Center, Bambino Gesù Children’s Hospital, IRCCS, Rome, Italy 
b Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy 
c Cellular Immunology Laboratory, INMI L Spallanzani – IRCCS, Rome, Italy 
d Virology Laboratory, INMI L Spallanzani – IRCCS, Rome, Italy 
g Pathology Unit, INMI L Spallanzani – IRCCS, Rome, Italy 
f Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy 
k Department of Clinical Medicine and Surgery, University of Naples Federico II, Rome, Italy 
l Catholic University of the Sacred Heart, Rome, Italy 

Corresponding author: Enrico Velardi, PhD, Department of Pediatric Hematology and Oncology, Cell and Gene Therapy, Bambino Gesù Children’s Hospital, IRCCS, Rome, 00146, Italy.Department of Pediatric Hematology and OncologyCell and Gene TherapyBambino Gesù Children’s HospitalIRCCSRome00146Italy

Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.

Connectez-vous pour en bénéficier!

Abstract

Background

Lymphopenia, particularly when restricted to the T-cell compartment, has been described as one of the major clinical hallmarks in patients with coronavirus disease 2019 (COVID-19) and proposed as an indicator of disease severity. Although several mechanisms fostering COVID-19–related lymphopenia have been described, including cell apoptosis and tissue homing, the underlying causes of the decline in T-cell count and function are still not completely understood.

Objective

Given that viral infections can directly target thymic microenvironment and impair the process of T-cell generation, we sought to investigate the impact of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) on thymic function.

Methods

We performed molecular quantification of T-cell receptor excision circles and κ-deleting recombination excision circles to assess, respectively, T- and B-cell neogenesis in SARS-CoV-2–infected patients. We developed a system for in vitro culture of primary human thymic epithelial cells (TECs) to mechanistically investigate the impact of SARS-CoV-2 on TEC function.

Results

We showed that patients with COVID-19 had reduced thymic function that was inversely associated with the severity of the disease. We found that angiotensin-converting enzyme 2, through which SARS-CoV-2 enters the host cells, was expressed by thymic epithelium, and in particular by medullary TECs. We also demonstrated that SARS-CoV-2 can target TECs and downregulate critical genes and pathways associated with epithelial cell adhesion and survival.

Conclusions

Our data demonstrate that the human thymus is a target of SARS-CoV-2 and thymic function is altered following infection. These findings expand our current knowledge of the effects of SARS-CoV-2 infection on T-cell homeostasis and suggest that monitoring thymic activity may be a useful marker to predict disease severity and progression.

Le texte complet de cet article est disponible en PDF.

Graphical abstract




Le texte complet de cet article est disponible en PDF.

Key words : COVID-19, SARS-CoV-2, immunodeficiency, thymus, T cells, thymic epithelial cells

Abbreviations used : ACE2, βTREC, cjKREC, CK1, CK5, COVID-19, cTEC, DEGs, EpCAM, hTEC, ICU, KREC, LCMV, mTEC, sjKREC, sjTREC, TEC, SARS-CoV-2, TREC, UEA1


Plan


 E.V. was supported by grants from the Amy Stelzer Manasevit Research Program, the Italian Association for Cancer Research (AIRC), and the Italian Ministry of Health (“Ricerca Corrente”). F.L. was supported by grants from AIRC (Special Program Metastatic disease: The Key Unmet Need in Oncology 5 per mille 2018 Project Code 21147 and Accelerator Award 2017 INCAR), Ministero dell’Istruzione dell’Università e della Ricerca (grant PRIN ID 2017 WC8499_004), and the Italian Ministry of Health (grant RF-2016-02364388). S.F and S.G. were supported by the AIRC fellowship for Italy. The study was also supported by the European Virus Archive - GLOBAL funded by European Union's Horizon 2020 research and innovation programme (grant agreement no. 871029).
 Disclosure of potential conflict of interest: The authors declare that they have no relevant conflicts of interest.


© 2023  The Authors. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 151 - N° 4

P. 911-921 - avril 2023 Retour au numéro
Article précédent Article précédent
  • 2022: The year in review
  • Zuhair K. Ballas
| Article suivant Article suivant
  • Functionally impaired antibody response to BNT162b2 booster vaccination in CVID IgG responders
  • Kai M.T. Sauerwein, Christoph B. Geier, Roman F. Stemberger, Raphael Rossmanith, Hüseyin Akyaman, Peter Illes, Michael B. Fischer, Martha M. Eibl, Jolan E. Walter, Hermann M. Wolf

Bienvenue sur EM-consulte, la référence des professionnels de santé.

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.